Affecting lives, page-8

First 8 Last

Share
Profile

Follow
manere

55 Posts.

30/10/15

17:05

Post #: 16295625
Share

Originally posted by TomBombadil ↑

You draw a rather long bow.
You have conflated his wound care expertise and knowing does it work to heal wounds
with
was the test sufficient to meet some other bodies legal requirements. Its true he would have much more knowledge of the latter than you or me through experience, but that is unrelated to his skills expertise and credibility as an eminent wound care specialist.

There is also the issue of having expertise not only in what the requirements were at the time but were going to be when the application was lodged. Back in that window of time was about when large problem with replacement hip devices blew up and the ramifications of that fell out.

The test was, Flawed for the purpose it was eventually put to. Questioning whether or not it did do what it did do well is different matter. I was as, I read the design always aware of the patient selection mechanisms, and that it was not a double blinded randomised trial, and was aware that it had been done by man with actual expertise in the field.
I never ever recall any assurance made by him that it was fit for the purpose you now critcize his expertise over.

I find no credible or reasonable basis for you questioning his expertise in his own field. The involvement of his expertise means what it always did, and regulatory risks are still in existence. Not only have we tripped on those once but they are still there.
The evidence that it works is the same as it always was. It is not rigorous enough for pharma application in the US.

As stated one of the bigger risks I see to current investors is that other people will talk the stock down and make it hard to get good financing deal and go forwards.

Expand

Are you talking to me TomBombadil? I'm not criticising a single person? I didn't refer to a single person? Don't really follow your post sorry, quite confusing.

TIS Price at posting: 4.7¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

HotCopper Highlights: Your most watched stocks for Week 48, 2024

There are more pages in this discussion • 7 more messages in this thread...

First 8 Last

Add TIS (ASX) to my watchlist

Affecting lives, page-8

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Resolute shares bounce back as second payment made to Mali government to secure workers' release

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

HotCopper Highlights: Your most watched stocks for Week 48, 2024